Ratings by Wedbush (David Nierengarten)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/20/2023 | 2Seventy Bio Inc. | TSVT | Downgrade | Neutral (Outperform) |
2.13 (1.83) |
-14.08% | Details | |
| 11/9/2023 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 11/9/2023 | Fate Therapeutics | FATE | Maintain | Neutral (N/A) |
|
Details | ||
| 11/7/2023 | bluebird bio | BLUE | Maintain | Neutral (N/A) |
|
Details | ||
| 10/26/2023 | AnaptysBio | ANAB | Maintain | Neutral (N/A) |
|
Details | ||
| 10/19/2023 | Beam Therapeutics Inc | BEAM | Maintain | Outperform (N/A) |
|
Details | ||
| 10/18/2023 | Freeline | FRLN | Downgrade | Neutral (Outperform) |
4.32 (6.31) |
46.06% | Details | |
| 9/22/2023 | ORIC Pharamceuticals | ORIC | New Coverage | Outperform (N/A) |
8.00 (7.90) |
-1.25% | Details | |
| 9/22/2023 | Ikena Oconology | IKNA | New Coverage | Outperform (N/A) |
4.31 (1.45) |
-66.36% | Details | |
| 9/19/2023 | Kinnate Biopharma | KNTE | Downgrade | Neutral (Outperform) |
1.70 (2.27) |
33.53% | Details | |
| 8/8/2023 | AnaptysBio | ANAB | Maintain | Neutral (N/A) |
|
Details | ||
| 8/8/2023 | Apogee Therapeutics Inc | APGE | New Coverage | Outperform (N/A) |
20.50 (19.51) |
-4.83% | Details | |
| 7/27/2023 | Mersana | MRSN | Downgrade | Neutral (Outperform) |
3.91 (1.65) |
-57.8% | Details | |
| 7/26/2023 | Karyopharm Therapeutics | KPTI | Maintain | Neutral (N/A) |
|
Details | ||
| 7/25/2023 | Kiniksa | KNSA | Maintain | Outperform (N/A) |
|
Details | ||
| 7/12/2023 | Avrobio Inc. | AVRO | Downgrade | Neutral (Outperform) |
0.98 (1.32) |
34.69% | Details | |
| 6/22/2023 | Tscan Therapeutics Inc | TCRX | New Coverage | Outperform (N/A) |
2.83 (6.53) |
130.74% | Details | |
| 6/7/2023 | NovoCure Ltd. | NVCR | Upgrade | Neutral (Underperform) |
82.51 (12.27) |
-85.13% | Details | |
| 5/30/2023 | Freeline | FRLN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/22/2023 | Avrobio Inc. | AVRO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2023 | Y-mAbs Therapeutics | YMAB | Upgrade | Outperform (Neutral) |
9.23 (6.21) |
-32.72% | Details | |
| 5/9/2023 | bluebird bio | BLUE | Maintain | Neutral (N/A) |
|
Details | ||
| 5/4/2023 | 2Seventy Bio Inc. | TSVT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/1/2023 | Iveric Bio | ISEE | Downgrade | Neutral (Outperform) |
32.89 (39.95) |
21.47% | Details | |
| 4/18/2023 | Kinnate Biopharma | KNTE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2023 | Kiniksa | KNSA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/24/2023 | Generation Bio | GBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2023 | Fusion Pharmaceuticals | FUSN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/13/2023 | G1 Therapeutics | GTHX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/26/2023 | Magenta Therapeutics | MGTA | Downgrade | Neutral (Outperform) |
0.50 (0.70) |
40% | Details | |
| 1/25/2023 | Fennec Pharmaceuticals Inc. | FENC | Maintain | Outperform (N/A) |
|
Details | ||
| 1/18/2023 | Nuvalent | NUVL | New Coverage | Outperform (N/A) |
32.43 (65.37) |
101.57% | Details | |
| 1/6/2023 | Fate Therapeutics | FATE | Downgrade | Neutral (Outperform) |
11.00 (2.49) |
-77.36% | Details | |
| 1/6/2023 | AnaptysBio | ANAB | Maintain | Neutral (N/A) |
|
Details | ||
| 1/4/2023 | Disc Medicine | IRON | New Coverage | Outperform (N/A) |
19.89 (55.18) |
177.43% | Details | |
| 12/20/2022 | Magenta Therapeutics | MGTA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2022 | Kinnate Biopharma | KNTE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2022 | Beam Therapeutics Inc | BEAM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2022 | Spring Works Therapeutics | SWTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2022 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 10/31/2022 | Y-mAbs Therapeutics | YMAB | Downgrade | Neutral (Outperform) |
8.93 (6.21) |
-30.46% | Details | |
| 10/24/2022 | Applied Genetic Technologies Corp. | AGTC | Downgrade | Neutral (Outperform) |
0.24 (0.39) |
62.5% | Details | |
| 10/19/2022 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 9/26/2022 | Fennec Pharmaceuticals Inc. | FENC | Maintain | Outperform (N/A) |
|
Details | ||
| 9/19/2022 | bluebird bio | BLUE | Maintain | Neutral (N/A) |
|
Details | ||
| 9/16/2022 | G1 Therapeutics | GTHX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2022 | Fusion Pharmaceuticals | FUSN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2022 | Mersana | MRSN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/3/2022 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 7/26/2022 | Vor Biopharma, Inc. | VOR | New Coverage | Outperform (N/A) |
4.76 (1.85) |
-61.13% | Details | |
| 7/11/2022 | Freeline | FRLN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/27/2022 | Epizyme | EPZM | Downgrade | Neutral (Outperform) |
0.95 (1.47) |
54.74% | Details | |
| 6/3/2022 | Turning Point Therapeutics Inc. | TPTX | Downgrade | Neutral (Outperform) |
34.16 (76.01) |
122.51% | Details | |
| 5/27/2022 | Spring Works Therapeutics | SWTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2022 | iTeos Therapeutics | ITOS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2022 | TCR2 Therapeutics | TCRR | Maintain | Neutral (N/A) |
|
Details | ||
| 5/10/2022 | Epizyme | EPZM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2022 | Beam Therapeutics Inc | BEAM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/29/2022 | Kinnate Biopharma | KNTE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/16/2022 | Inozyme Pharma Inc. | INZY | Maintain | Outperform (N/A) |
|
Details | ||
| 3/8/2022 | Magenta Therapeutics | MGTA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/7/2022 | bluebird bio | BLUE | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2022 | Fennec Pharmaceuticals Inc. | FENC | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2022 | Beam Therapeutics Inc | BEAM | Maintain | Outperform (N/A) |
|
Details | ||
| 2/22/2022 | Codiak Biosciences Inc. | CDAK | Maintain | Outperform (N/A) |
|
Details | ||
| 2/16/2022 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 2/3/2022 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 2/3/2022 | Mersana | MRSN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/11/2022 | Applied Genetic Technologies Corp. | AGTC | Maintain | Outperform (N/A) |
|
Details | ||
| 1/11/2022 | 2Seventy Bio Inc. | TSVT | Maintain | Outperform (N/A) |
|
Details | ||
| 1/10/2022 | TCR2 Therapeutics | TCRR | Maintain | Neutral (N/A) |
|
Details | ||
| 1/10/2022 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 1/10/2022 | Scholar Rock | SRRK | Maintain | Outperform (N/A) |
|
Details | ||
| 1/10/2022 | Karyopharm Therapeutics | KPTI | Maintain | Neutral (N/A) |
|
Details | ||
| 1/10/2022 | NovoCure Ltd. | NVCR | Maintain | Underperform (N/A) |
|
Details | ||
| 1/7/2022 | Mersana | MRSN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2022 | Kinnate Biopharma | KNTE | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2022 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 1/4/2022 | Avrobio Inc. | AVRO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/15/2021 | Fate Therapeutics | FATE | Upgrade | Outperform (Neutral) |
46.44 (2.49) |
-94.64% | Details | |
| 12/14/2021 | Generation Bio | GBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/14/2021 | Freeline | FRLN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/29/2021 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 11/22/2021 | Chimerix | CMRX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/22/2021 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2021 | Kinnate Biopharma | KNTE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2021 | Mersana | MRSN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2021 | 2Seventy Bio Inc. | TSVT | New Coverage | Outperform (N/A) |
33.62 (1.83) |
-94.56% | Details | |
| 11/8/2021 | bluebird bio | BLUE | Maintain | Neutral (N/A) |
|
Details | ||
| 11/5/2021 | Orchard Therapeutics | ORTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2021 | AnaptysBio | ANAB | Maintain | Neutral (N/A) |
|
Details | ||
| 11/5/2021 | Spring Works Therapeutics | SWTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2021 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2021 | Magenta Therapeutics | MGTA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2021 | Karyopharm Therapeutics | KPTI | Maintain | Neutral (N/A) |
|
Details | ||
| 10/28/2021 | NovoCure Ltd. | NVCR | Maintain | Underperform (N/A) |
|
Details | ||
| 10/26/2021 | AnaptysBio | ANAB | Maintain | Neutral (N/A) |
|
Details | ||
| 10/14/2021 | G1 Therapeutics | GTHX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/8/2021 | Turning Point Therapeutics Inc. | TPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/17/2021 | TCR2 Therapeutics | TCRR | Downgrade | Neutral (Outperform) |
15.72 (1.48) |
-90.59% | Details | |
| 9/10/2021 | Iveric Bio | ISEE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/2/2021 | NovoCure Ltd. | NVCR | Maintain | Underperform (N/A) |
|
Details | ||
| 8/16/2021 | Freeline | FRLN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/16/2021 | Cogent | COGT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2021 | Fennec Pharmaceuticals Inc. | FENC | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2021 | Karyopharm Therapeutics | KPTI | Maintain | Neutral (N/A) |
|
Details | ||
| 8/4/2021 | Iveric Bio | ISEE | Maintain | Outperform (N/A) |
|
Details | ||
| 7/21/2021 | Magenta Therapeutics | MGTA | Maintain | Outperform (N/A) |
|
Details | ||
| 7/14/2021 | Generation Bio | GBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 6/29/2021 | Orchard Therapeutics | ORTX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/29/2021 | Beam Inc | BEAM | Maintain | Outperform (N/A) |
|
Details | ||
| 6/28/2021 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 6/16/2021 | MacroGenics | MGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/18/2021 | Nuvation Bio Inc | NUVB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/18/2021 | Kinnate Biopharma | KNTE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2021 | Cogent | COGT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/11/2021 | Mersana | MRSN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2021 | Chimerix | CMRX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2021 | Fate Therapeutics | FATE | Upgrade | Outperform (Neutral) |
77.73 (2.49) |
-96.8% | Details | |
| 5/6/2021 | Epizyme | EPZM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2021 | Spring Works Therapeutics | SWTX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/14/2021 | NovoCure Ltd. | NVCR | Downgrade | Neutral (Outperform) |
197.33 (12.27) |
-93.78% | Details | |
| 4/13/2021 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 3/31/2021 | Chimerix | CMRX | New Coverage | Outperform (N/A) |
8.59 (0.97) |
-88.71% | Details | |
| 3/25/2021 | iTeos Therapeutics | ITOS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2021 | Codiak Biosciences Inc. | CDAK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/15/2021 | Beam Inc | BEAM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2021 | TCR2 Therapeutics | TCRR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2021 | AnaptysBio | ANAB | Downgrade | Neutral (Outperform) |
19.51 (14.14) |
-27.52% | Details | |
| 3/8/2021 | Nuvation Bio Inc | NUVB | New Coverage | Outperform (N/A) |
10.86 (1.24) |
-88.58% | Details | |
| 2/26/2021 | Y-mAbs Therapeutics | YMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2021 | Mersana | MRSN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2021 | Fate Therapeutics | FATE | Downgrade | Neutral (Outperform) |
86.27 (2.49) |
-97.11% | Details | |
| 2/25/2021 | Spring Works Therapeutics | SWTX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/24/2021 | Beam Inc | BEAM | Maintain | Outperform (N/A) |
|
Details | ||
| 2/16/2021 | G1 Therapeutics | GTHX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/16/2021 | bluebird bio | BLUE | Downgrade | Neutral (Outperform) |
45.76 (3.82) |
-91.65% | Details | |
| 1/29/2021 | Turning Point Therapeutics Inc. | TPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/30/2020 | Codiak Biosciences Inc. | CDAK | Maintain | Outperform (N/A) |
|
Details | ||
| 12/28/2020 | Kinnate Biopharma | KNTE | New Coverage | Outperform (N/A) |
38.00 (2.27) |
-94.03% | Details | |
| 12/21/2020 | Karyopharm Therapeutics | KPTI | Maintain | Neutral (N/A) |
|
Details | ||
| 12/17/2020 | MacroGenics | MGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/14/2020 | TCR2 Therapeutics | TCRR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/12/2020 | Spring Works Therapeutics | SWTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2020 | Aravive Inc. | ARAV | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2020 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2020 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 11/5/2020 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2020 | Epizyme | EPZM | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2020 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2020 | Scholar Rock | SRRK | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2020 | AnaptysBio | ANAB | Upgrade | Outperform (Neutral) |
27.73 (14.14) |
-49.01% | Details | |
| 10/19/2020 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 10/13/2020 | Turning Point Therapeutics Inc. | TPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/5/2020 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/22/2020 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 9/10/2020 | Sutro Biopharma | STRO | Maintain | Outperform (N/A) |
|
Details | ||
| 8/19/2020 | Turning Point Therapeutics Inc. | TPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/18/2020 | iTeos Therapeutics | ITOS | New Coverage | Outperform (N/A) |
32.92 (9.36) |
-71.57% | Details | |
| 8/18/2020 | Inozyme Pharma Inc. | INZY | Maintain | Outperform (N/A) |
|
Details | ||
| 8/13/2020 | Spring Works Therapeutics | SWTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2020 | Fennec Pharmaceuticals Inc. | FENC | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2020 | Syros Pharmaceuticals | SYRS | Maintain | Neutral (N/A) |
|
Details | ||
| 8/6/2020 | Orchard Therapeutics | ORTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2020 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2020 | G1 Therapeutics | GTHX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2020 | Iveric Bio | ISEE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2020 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2020 | Karyopharm Therapeutics | KPTI | Maintain | Neutral (N/A) |
|
Details | ||
| 7/31/2020 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/31/2020 | MacroGenics | MGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/27/2020 | TCR2 Therapeutics | TCRR | Maintain | Outperform (N/A) |
|
Details | ||
| 7/23/2020 | Aravive Inc. | ARAV | Maintain | Outperform (N/A) |
|
Details | ||
| 7/21/2020 | Fusion Pharmaceuticals | FUSN | New Coverage | Outperform (N/A) |
15.28 (5.54) |
-63.74% | Details | |
| 7/7/2020 | Generation Bio | GBIO | New Coverage | Outperform (N/A) |
19.64 (1.13) |
-94.25% | Details | |
| 7/7/2020 | Unum Therapeutics | UMRX | Upgrade | Outperform (Neutral) |
2.20 (2.35) |
6.82% | Details | |
| 6/29/2020 | Kiniksa | KNSA | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2020 | Mersana | MRSN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/1/2020 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 5/27/2020 | Mersana | MRSN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/18/2020 | Merus N.V. | MRUS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2020 | Turning Point Therapeutics Inc. | TPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2020 | Spring Works Therapeutics | SWTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2020 | Spring Works Therapeutics | SWTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2020 | Sutro Biopharma | STRO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/11/2020 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/11/2020 | Y-mAbs Therapeutics | YMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2020 | Orchard Therapeutics | ORTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2020 | Stemline Therapeutics | STML | Downgrade | Neutral (Outperform) |
4.75 (11.83) |
149.05% | Details | |
| 5/1/2020 | NovoCure Ltd. | NVCR | Maintain | Neutral (N/A) |
|
Details | ||
| 4/28/2020 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 4/3/2020 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/26/2020 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/24/2020 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2020 | Stemline Therapeutics | STML | Maintain | Outperform (N/A) |
|
Details | ||
| 3/4/2020 | Unum Therapeutics | UMRX | Downgrade | Neutral (Outperform) |
0.53 (2.35) |
343.4% | Details | |
| 3/2/2020 | Mersana | MRSN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2020 | Beam Inc | BEAM | New Coverage | Outperform (N/A) |
22.49 (28.08) |
24.86% | Details | |
| 2/27/2020 | G1 Therapeutics | GTHX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2020 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2020 | Intellia Therapeutics | NTLA | Downgrade | Neutral (Outperform) |
15.51 (29.63) |
91.04% | Details | |
| 2/11/2020 | Avrobio Inc. | AVRO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/24/2020 | Epizyme | EPZM | Maintain | Outperform (N/A) |
|
Details | ||
| 1/23/2020 | Applied Genetic Technologies Corp. | AGTC | Maintain | Outperform (N/A) |
|
Details | ||
| 1/21/2020 | MacroGenics | MGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/17/2020 | Syros Pharmaceuticals | SYRS | Downgrade | Neutral (Outperform) |
9.20 (2.75) |
-70.11% | Details | |
| 1/17/2020 | Karyopharm Therapeutics | KPTI | Downgrade | Neutral (Outperform) |
18.83 (0.77) |
-95.91% | Details | |
| 1/17/2020 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 1/16/2020 | Stemline Therapeutics | STML | Maintain | Outperform (N/A) |
|
Details | ||
| 1/16/2020 | Stemline Therapeutics | STML | Maintain | Outperform (N/A) |
|
Details | ||
| 1/15/2020 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 1/10/2020 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2020 | Iveric Bio | ISEE | New Coverage | Outperform (N/A) |
8.14 (39.95) |
390.79% | Details | |
| 12/9/2019 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/3/2019 | Audentes Therapeutics | BOLD | Downgrade | Neutral (Outperform) |
28.61 (59.97) |
109.61% | Details | |
| 11/20/2019 | Aravive Inc. | ARAV | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2019 | resTORbio Inc. | TORC | Downgrade | Neutral (Outperform) |
7.95 (2.28) |
-71.32% | Details | |
| 11/13/2019 | Scholar Rock | SRRK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2019 | AnaptysBio | ANAB | Downgrade | Neutral (Outperform) |
36.16 (14.14) |
-60.9% | Details | |
| 11/4/2019 | bluebird bio | BLUE | Upgrade | Outperform (Neutral) |
82.86 (45.76) |
-44.77% | Details | |
| 10/28/2019 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 10/23/2019 | MacroGenics | MGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/8/2019 | Spring Works Therapeutics | SWTX | New Coverage | Outperform (N/A) |
18.67 (30.39) |
62.77% | Details | |
| 9/27/2019 | Applied Genetic Technologies Corp. | AGTC | Maintain | Outperform (N/A) |
|
Details | ||
| 9/17/2019 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 9/10/2019 | Turning Point Therapeutics Inc. | TPTX | New Coverage | Outperform (N/A) |
42.75 (76.01) |
77.8% | Details | |
| 9/9/2019 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 9/4/2019 | Y-mAbs Therapeutics Inc. | YMAB | New Coverage | Outperform () |
0.80 (6.21) |
676.25% | Details | |
| 8/21/2019 | Synlogic Inc. | SYBX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2019 | MyoKardia | MYOK | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2019 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2019 | Fate Therapeutics | FATE | Maintain | (N/A) |
|
Details | ||
| 8/2/2019 | Stemline Therapeutics | STML | Upgrade | Outperform (Neutral) |
13.03 (4.75) |
-63.55% | Details | |
| 7/26/2019 | NovoCure Ltd. | NVCR | Downgrade | Neutral (Outperform) |
70.99 (12.27) |
-82.72% | Details | |
| 7/5/2019 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 6/21/2019 | AnaptysBio | ANAB | Maintain | Outperform (N/A) |
|
Details | ||
| 6/18/2019 | Voyager Therapeutics | VYGR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/17/2019 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2019 | Stemline Therapeutics | STML | Downgrade | Neutral (Outperform) |
16.08 (13.03) |
-18.97% | Details | |
| 5/3/2019 | Intellia Therapeutics | NTLA | Upgrade | Outperform (Neutral) |
14.46 (15.51) |
7.26% | Details | |
| 5/3/2019 | MacroGenics | MGNX | Upgrade | Outperform (Neutral) |
16.78 (8.21) |
-51.07% | Details | |
| 4/9/2019 | Audentes Therapeutics | BOLD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/9/2019 | Aravive Inc. | ARAV | New Coverage | Outperform (N/A) |
6.97 (0.15) |
-97.85% | Details | |
| 4/9/2019 | Aravive Inc. | AVAV | New Coverage | Outperform (N/A) |
18.53 (137.61) |
642.63% | Details | |
| 3/18/2019 | resTORbio Inc. | TORC | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2019 | Kiniksa | KNSA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2019 | Mersana | MRSN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2019 | TCR2 Therapeutics | TCRR | New Coverage | Outperform (N/A) |
18.02 (15.72) |
-12.76% | Details | |
| 3/5/2019 | MyoKardia | MYOK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/4/2019 | Nightstar Therapeutics | NITE | Downgrade | Neutral (Outperform) |
15.16 (25.41) |
67.61% | Details | |
| 3/4/2019 | Sutro Biopharma | STRO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2019 | NovoCure Ltd. | NVCR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2019 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2019 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2019 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/25/2019 | Clementia Pharmaceuticals Inc. | CMTA | Downgrade | Neutral (Outperform) |
14.94 (26.35) |
76.37% | Details | |
| 2/25/2019 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 2/20/2019 | Spark Therapeutics | ONCE | Maintain | Neutral (N/A) |
|
Details | ||
| 2/7/2019 | MacroGenics | MGNX | Downgrade | Neutral (Outperform) |
25.60 (16.78) |
-34.45% | Details | |
| 1/30/2019 | Voyager Therapeutics | VYGR | Maintain | Outperform (N/A) |
|
Details | ||
| 1/22/2019 | MacroGenics | MGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/2/2019 | MyoKardia | MYOK | Maintain | Outperform (N/A) |
|
Details | ||
| 12/4/2018 | Tesaro | TSRO | Downgrade | Neutral (Outperform) |
73.50 (74.96) |
1.99% | Details | |
| 11/26/2018 | Orchard Therapeutics | ORTX | New Coverage | Outperform (N/A) |
16.04 (16.21) |
1.06% | Details | |
| 11/9/2018 | AnaptysBio | ANAB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2018 | Karyopharm Therapeutics | KPTI | Upgrade | Outperform (Neutral) |
11.92 (18.83) |
57.97% | Details | |
| 11/8/2018 | Voyager Therapeutics | VYGR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2018 | Spark Therapeutics | ONCE | Upgrade | Neutral (Underperform) |
44.02 (110.05) |
150% | Details | |
| 11/2/2018 | Intellia Therapeutics | NTLA | Downgrade | Neutral (Outperform) |
16.98 (14.46) |
-14.84% | Details | |
| 10/22/2018 | Sutro Biopharma | STRO | New Coverage | Outperform (N/A) |
14.55 (2.61) |
-82.06% | Details | |
| 10/10/2018 | Applied Genetic Technologies Corp. | AGTC | Maintain | Outperform (N/A) |
|
Details | ||
| 10/8/2018 | Audentes Therapeutics | BOLD | Maintain | Outperform (N/A) |
|
Details | ||
| 9/26/2018 | NovoCure Ltd. | NVCR | Maintain | Outperform (N/A) |
|
Details | ||
| 9/25/2018 | Nightstar Therapeutics | NITE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/20/2018 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2018 | Unum Therapeutics | UMRX | Maintain | Outperform (N/A) |
|
Details |
